Aminoglycoside resistance among Danish blood culture isolates of coagulase-negative staphylococci. 1996

C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
Sector of Microbiology, Statens Serum Institut, Copenhagen, Denmark.

A sample of 137 coagulase-negative staphylococci isolated from blood cultures in Denmark over a 4-month period during 1992-1993 were tested for aminoglycoside resistance and for the presence of aminoglycoside-modifying enzymes. This was done on the basis of minimum inhibitory concentrations (MICs) measured by agar dilution, inhibition zone diameter by disk diffusion, and DNA dot blot analysis. Using the National Committee for Clinical Laboratory Standards (NCCLS) MIC breakpoints, 5%, 46%, 57%, and 63% of the strains were resistant to netilmicin, amikacin, gentamicin and tobramycin, respectively. The large majority of resistant staphylococci strains produced the bifunctional AAC(6)-III+APH(2") enzyme. The presence of AAC(6)-III+APH(2") explains the high level of resistance to gentamicin, kanamycin and tobramycin. In contrast to our results. Staphylococcus haemolyticus strains are usually reported to be more resistant than Staphylococcus epidermidis strains.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009693 Nucleic Acid Hybridization Widely used technique which exploits the ability of complementary sequences in single-stranded DNAs or RNAs to pair with each other to form a double helix. Hybridization can take place between two complimentary DNA sequences, between a single-stranded DNA and a complementary RNA, or between two RNA sequences. The technique is used to detect and isolate specific sequences, measure homology, or define other characteristics of one or both strands. (Kendrew, Encyclopedia of Molecular Biology, 1994, p503) Genomic Hybridization,Acid Hybridization, Nucleic,Acid Hybridizations, Nucleic,Genomic Hybridizations,Hybridization, Genomic,Hybridization, Nucleic Acid,Hybridizations, Genomic,Hybridizations, Nucleic Acid,Nucleic Acid Hybridizations
D003030 Coagulase Enzymes that cause coagulation in plasma by forming a complex with human PROTHROMBIN. Coagulases are produced by certain STAPHYLOCOCCUS and YERSINIA PESTIS. Staphylococci produce two types of coagulase: Staphylocoagulase, a free coagulase that produces true clotting of plasma, and Staphylococcal clumping factor, a bound coagulase in the cell wall that induces clumping of cells in the presence of fibrinogen. Staphylocoagulase,Staphylococcal Clumping Factor,Clumping Factor (Staphylococcal),Staphylococcus aureus clone pSCa2 of Coagulase,Staphylococcus aureus strain 213 of Coagulase,Staphylococcus aureus strain 8325-4 of Coagulase,Clumping Factor, Staphylococcal,Factor, Staphylococcal Clumping,Staphylococcus aureus strain 8325 4 of Coagulase
D003718 Denmark A country in northern Europe, bordering the Baltic Sea and the North Sea. The capital is Copenhagen. Faeroe Islands,Faroe Islands
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013203 Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. Infections, Staphylococcal,Staphylococcus aureus Infection,Staphylococcal Infection,Staphylococcus aureus Infections

Related Publications

C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
July 1984, Journal of clinical microbiology,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
November 2004, The Journal of antimicrobial chemotherapy,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
March 2007, The Annals of pharmacotherapy,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
July 1997, Journal of clinical microbiology,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
November 1987, Antimicrobial agents and chemotherapy,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
January 2012, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
January 2020, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
April 1985, Journal of medical microbiology,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
December 1993, Journal of medical microbiology,
C Busch-Sørensen, and N Frimodt-Møller, and G H Miller, and F Espersen
October 2006, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!